Union Bankshares Corp increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.2% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 54,867 shares of the company’s stock after buying an additional 85 shares during the quarter. Johnson & Johnson comprises approximately 2.5% of Union Bankshares Corp’s portfolio, making the stock its 3rd largest position. Union Bankshares Corp’s holdings in Johnson & Johnson were worth $7,259,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in JNJ. Bouchey Financial Group Ltd raised its position in shares of Johnson & Johnson by 5.8% during the 1st quarter. Bouchey Financial Group Ltd now owns 3,167 shares of the company’s stock valued at $394,000 after buying an additional 175 shares during the period. Dynamic Advisors Solutions LLC raised its position in shares of Johnson & Johnson by 0.3% during the 1st quarter. Dynamic Advisors Solutions LLC now owns 19,487 shares of the company’s stock valued at $2,427,000 after buying an additional 56 shares during the period. Lynch & Associates IN raised its position in shares of Johnson & Johnson by 0.9% during the 1st quarter. Lynch & Associates IN now owns 92,869 shares of the company’s stock valued at $11,567,000 after buying an additional 826 shares during the period. Koshinski Asset Management Inc. raised its position in shares of Johnson & Johnson by 24.6% during the 1st quarter. Koshinski Asset Management Inc. now owns 15,127 shares of the company’s stock valued at $1,884,000 after buying an additional 2,988 shares during the period. Finally, Quadrant Capital Group LLC raised its position in shares of Johnson & Johnson by 14.5% during the 1st quarter. Quadrant Capital Group LLC now owns 13,240 shares of the company’s stock valued at $1,632,000 after buying an additional 1,679 shares during the period. 65.90% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson (NYSE:JNJ) traded up 0.01% during trading on Thursday, hitting $132.90. 994,874 shares of the company’s stock traded hands. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08. The stock has a market cap of $356.70 billion, a P/E ratio of 22.49 and a beta of 0.78. The firm’s 50-day moving average price is $132.26 and its 200 day moving average price is $129.80.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business had revenue of $18.84 billion for the quarter, compared to the consensus estimate of $18.94 billion. During the same quarter last year, the firm posted $1.74 EPS. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. Analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.53%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 56.76%.

Several analysts recently weighed in on JNJ shares. UBS AG reiterated a “buy” rating and issued a $148.00 target price (up previously from $136.00) on shares of Johnson & Johnson in a report on Wednesday, July 19th. Goldman Sachs Group, Inc. (The) downgraded shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and lifted their target price for the company from $125.00 to $130.00 in a report on Wednesday, September 20th. BMO Capital Markets reiterated a “buy” rating and issued a $145.00 target price on shares of Johnson & Johnson in a report on Friday, September 1st. Alembic Global Advisors downgraded shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Finally, BidaskClub upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Five investment analysts have rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $134.79.

In other news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the transaction, the vice president now owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now directly owns 230,342 shares in the company, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) Stake Increased by Union Bankshares Corp” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/johnson-johnson-jnj-stake-increased-by-union-bankshares-corp/1610304.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.